- TLDR Biotech
- Archive
- Page -13
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | May 4 - 5, 2025
European Commission pledges €500M ($568M) in research funding to attract scientists amid US funding cuts, Deerfield Management raises $600M Healthcare Innovations Fund to invest in therapeutics and AI, Novo Nordisk's oral Wegovy (semaglutide) formulation awaits FDA approval decision by Q4, Bristol Myers Squibb cutting 516 more jobs in New Jersey + 31 more stories
Biotech & Pharma Updates | May 1 - 4, 2025
Aviva Capital Partners announces plans for £1B ($1.3B) cancer research and treatment hub in London, Kura Oncology earns $45M milestone payment from Kyowa Kirin for ziftomenib NDA submission in acute leukemias, Amgen executives advocate for tax incentives (not tariffs) to boost US pharmaceutical manufacturing, Pliant Therapeutics cuts 45% of workforce to extend cash ahead of results from halted idiopathic pulmonary fibrosis drug study + 26 more stories
Biotech & Pharma Updates | April 30 - May 1, 2025
Siren Biotechnology tries crowdfunding, Eli Lilly shares drop after CVS removes Zepbound from coverage lists, Samsung Biologics signs $518M contract with US pharma through 2031, Kronos Bio agrees to acquisition by Kevin Tang's Concentra Biosciences for $0.57 per share plus contingent value rights + 37 more stories
Biotech & Pharma Updates | April 29 - 30, 2025
Novartis scoops up Regulus Tx for up to $1.7B, Regeneron's Lynozyfic bispecific lands EU approval for multiple myeloma, Zeon Systems launches with AI-driven robotics for laboratory automation (turning natural language into experimental design) + 30 more stories
Biotech & Pharma Updates | April 28 - 29, 2025
Novo Nordisk and Hims & Hers partner to offer discounted Wegovy through telehealth platform after settling compounding dispute, Abeona Therapeutics' Zevaskyn (a skin cell therapy) received FDA approval for epidermolysis bullosa at $3.1 million list price + 38 more stories
Biotech & Pharma Updates | April 27 - 28, 2025
Merck KGaA to acquire SpringWorks Therapeutics for $3.9bn, Novavax believes its COVID-19 vaccine application is approvable despite FDA request for postmarketing clinical trial commitment, Biohaven $600M strategic investment from Oberland Capital, HSBC downgrades Eli Lilly stock due to high valuation and competition from Novo Nordisk + 31 more stories
Biotech & Pharma Updates | April 24 - 27, 2025
Summit Tx shares plunge after Akeso reveals less-than-stellar overall survival data for Keytruda-challenging bispecific, Pfizer's anti-PD-1 mAb delivers positive Ph3 results in high-risk non-muscle invasive bladder cancer, AbbVie plans $10B US investment over next decade including four new manufacturing facilities, Novavax may need to conduct another clinical trial for its COVID-19 vaccine + 34 more stories
Biotech & Pharma Updates | April 23 - 24, 2025
Granite Bio's $100M launch going after I&I, Sanofi reports strong Q1 earnings, Thermo Fisher joins the US manufacturing rush with $2B commitment, Merck & Co.'s $200M tariff warning, FDA's drug safety databases neglected after sweeping agency layoffs + 29 more stories
Biotech & Pharma Updates | April 22 - 23, 2025
Eli Lilly continues crusade against unauthorized GLP-1 sales, AI-powered ADC developer launches from stealth with $20M, Claris Ventures first closing of targeting $114M Italy-focused biotech fund, Sanofi returns NK cell engager SAR443579 to Innate Pharma, Illumina telegraphs more San Diego layoffs + 20 more stories
Biotech & Pharma Updates | April 21 - 22, 2025
Roche pledges $50B to expand US drug production, AstraZeneca rejoins PhRMA, Biolinq $100M Series C for intradermal biosensors in glucose monitoring, B Cobenfy (xanomeline/trospium chloride), an M1/M4 muscarinic receptor agonist, failed Ph3 trial as add-on therapy for schizophrenia.
Biotech & Pharma Updates | April 18 - 21, 2025
Novo Nordisk submits oral GLP-1 approval application to FDA, Alis Biosciences launches fund to unlock trapped capital from public biotech companies with depressed valuations, Tempest Therapeutics lays off 80% of staff following strategic alternatives announcement + more NIH and federal funding chaos